The 6 most recent market catalysts affecting $JUNS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 60
Jupiter Neurosciences Commences ~$2M Offering Of 307,692 Common Shares
Jupiter Neurosciences is conducting a registered direct offering to raise approximately $2.0 million by selling 307,692 shares of common stock. This event is a capital raise, which…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 75
Jupiter Neurosciences shares are trading higher after the company's related biotechnology partner, PharmAla Biotech Holdings, announced a series of corporate updates, including a newly granted U.S. patent.
This headline indicates a significant positive catalyst for Jupiter Neurosciences, driven by its partner PharmAla Biotech's corporate updates, particularly the new U.S. patent. A p…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 85
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?
Jupiter Neurosciences (JUNS) experienced a significant premarket surge following announcements from its partner, PharmAla Biotech. The key drivers are PharmAla securing a new U.S. …
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 75
Jupiter Neurosciences Announces 1-For-75 Reverse Stock Split, Effective Aug. 6
Jupiter Neurosciences is implementing a 1-for-75 reverse stock split, a corporate action where the number of outstanding shares is reduced, and the price per share is proportionall…
Jul 21, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This filing details the pre-market trading activity for several health care stocks, highlighting both significant gainers and losers. These movements are typically driven by compan…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments
Jupiter Neurosciences (JUNS) has secured perpetual exclusive U.S. rights to ALA-002, an FDA NCE-designated non-racemic MDMA, from PharmAla Biotech. This transaction is a significan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.